NZ507621A - HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy - Google Patents

HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy

Info

Publication number
NZ507621A
NZ507621A NZ507621A NZ50762100A NZ507621A NZ 507621 A NZ507621 A NZ 507621A NZ 507621 A NZ507621 A NZ 507621A NZ 50762100 A NZ50762100 A NZ 50762100A NZ 507621 A NZ507621 A NZ 507621A
Authority
NZ
New Zealand
Prior art keywords
hcv
ribavirin
rna
combination therapy
eradication
Prior art date
Application number
NZ507621A
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ507621(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ507621A publication Critical patent/NZ507621A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ507621A 1998-05-15 2000-10-18 HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy NZ507621A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
NZ507621A true NZ507621A (en) 2002-11-26

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507621A NZ507621A (en) 1998-05-15 2000-10-18 HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy

Country Status (22)

Country Link
EP (3) EP1213029A1 (enExample)
JP (2) JP5281726B2 (enExample)
KR (1) KR100694345B1 (enExample)
CN (1) CN1230198C (enExample)
AR (1) AR019551A1 (enExample)
AT (1) ATE216591T1 (enExample)
AU (2) AU766597B2 (enExample)
BR (1) BR9910505A (enExample)
CA (1) CA2331823A1 (enExample)
CZ (1) CZ300540B6 (enExample)
DE (1) DE69901321T2 (enExample)
DK (1) DK0956861T3 (enExample)
ES (1) ES2172288T3 (enExample)
HU (1) HU230432B1 (enExample)
IL (3) IL139220A0 (enExample)
MY (1) MY129244A (enExample)
NO (1) NO330715B1 (enExample)
NZ (1) NZ507621A (enExample)
PT (1) PT956861E (enExample)
SK (1) SK288038B6 (enExample)
TW (1) TWI277424B (enExample)
WO (1) WO1999059621A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CA2384326A1 (en) * 1999-12-23 2001-06-28 Johnson Lau Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
HK1052878A1 (zh) * 2000-10-18 2003-10-03 Schering Corporation 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
AU2002365436B8 (en) * 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN1980678A (zh) * 2003-03-28 2007-06-13 法莫赛特股份有限公司 治疗黄病毒感染的化合物
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
MXPA05011170A (es) * 2003-04-17 2005-12-14 Ares Trading Sa Interferon beta en el sindrome respiratorio agudo severo.
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2004108151A1 (en) * 2003-06-09 2004-12-16 Genome Institute Of Singapore Inhibition of sars coronavirus infection with clinically approved antiviral drugs
AU2004264255A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd Method of treating viral infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2769377T3 (es) 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
ES2422556T3 (es) * 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
KR20100056479A (ko) 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
JP2013542206A (ja) * 2010-10-05 2013-11-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
KR20140147657A (ko) * 2011-03-02 2014-12-30 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001514936A (ja) 1997-08-13 2001-09-18 ボストン サイエンティフィック コーポレイション 水不溶性薬剤の装填および放出
ES2186660T3 (es) * 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

Also Published As

Publication number Publication date
DE69901321T2 (de) 2002-12-12
CZ20004177A3 (cs) 2001-04-11
JP2011173898A (ja) 2011-09-08
NO20005755L (no) 2001-01-12
KR100694345B1 (ko) 2007-03-12
HU230432B1 (hu) 2016-06-28
WO1999059621A1 (en) 1999-11-25
PT956861E (pt) 2002-08-30
AU2005220271B2 (en) 2005-11-03
DK0956861T3 (da) 2002-07-01
EP0956861A1 (en) 1999-11-17
ES2172288T3 (es) 2002-09-16
ATE216591T1 (de) 2002-05-15
CN1230198C (zh) 2005-12-07
HK1021131A1 (en) 2000-06-02
IL139220A (en) 2013-02-28
SK17102000A3 (sk) 2001-05-10
CA2331823A1 (en) 1999-11-25
NO20005755D0 (no) 2000-11-14
HUP0103423A2 (hu) 2002-01-28
JP5281726B2 (ja) 2013-09-04
IL207259A (en) 2016-08-31
JP2002515453A (ja) 2002-05-28
TWI277424B (en) 2007-04-01
NO330715B1 (no) 2011-06-20
EP0956861B1 (en) 2002-04-24
EP1213029A1 (en) 2002-06-12
BR9910505A (pt) 2001-01-02
MY129244A (en) 2007-03-30
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
AR019551A1 (es) 2002-02-27
CZ300540B6 (cs) 2009-06-10
HUP0103423A3 (en) 2003-11-28
KR20010043624A (ko) 2001-05-25
AU766597B2 (en) 2003-10-16
AU3860099A (en) 1999-12-06
AU2005220271A1 (en) 2005-11-03
IL207259A0 (en) 2010-12-30
SK288038B6 (en) 2013-01-02
IL139220A0 (en) 2001-11-25
AU2005220271B8 (en) 2010-11-18
DE69901321D1 (de) 2002-05-29
EP2305287A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
NZ507621A (en) HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
HK1052878A1 (zh) 利巴传林-聚乙二醇化干扰素α：丙型肝炎病毒的联合治疗
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
NO20011789L (no) Ribavirin-interferon <alfa> kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
James Ribavirin approved for hepatitis C combination treatment
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
Baker FDA approves new combination treatment for hepatitis C. Food and Drug Administration
TH46769A (th) การรักษาร่วมของ hcv
TH33755A (th) การรักษาร่วมเพื่อขจัด hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่ติดเชื้อตับอักเสบ c เรื้อรัง
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
TH53874A3 (th) การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired